Navigation Links
Experimental Drug Fights Multiple Sclerosis Activity
Date:6/20/2008

It led to a reduction of lesions seen on MRIs with limited side effects, study found

FRIDAY, June 20 (HealthDay News) -- One of the first pills to treat the "relapse-remitting" form of multiple sclerosis has been shown to help fight the disease with few side effects.

Although the drug, laquinimod, is still experimental, having a pill available would make therapy much more convenient for many patients.

"By and large, this doesn't look as strong as the strongest injectable drugs like Tysabri... but, in general, I believe that patients and companies feel that the advantage of having an oral drug makes these attractive additions to our therapeutic armamentarium," said Dr. John Richert, executive vice president for research and clinical programs at the National Multiple Sclerosis Society.

"Patients are more likely to stay on an oral drug. We'll need to see what comes out of Phase 3 trials [the current trial was a Phase 2 study]. At this point, it's encouraging, and certainly patients are thirsting for oral options," Richert added.

The study, funded by Teva Pharmaceutical Industries, is published in the June 21 issue of The Lancet. Earlier results from the same trial were presented this spring at the annual meeting of the American Academy of Neurology.

Multiple sclerosis affects the central nervous system and is thought to be an autoimmune disease. It primarily strikes "white matter" -- the tissues in the brain and the other parts of the nervous system that transmit messages between "gray matter," where nerve bodies are found. Symptoms range from the mild (numbness in the limb) to severe, including paralysis and loss of vision. There are four different "courses" of the disease, the most common being relapse-remitting MS, in which flare-ups alternate with partial or complete remissions.

Several treatments are available for MS; all are injectable.

Testing of an earlier, rel
'/>"/>

Copyright©2008 ScoutNews,LLC.
All rights reserved  

Page: 1 2 3

Related medicine news :

1. Experimental anti-cancer drug made from corn lillies kills brain tumor stem cells
2. Experimental Antidepressants Offer Faster Relief
3. Experimental drug shows promise in advanced kidney cancer
4. Experimental drug boosts survival in recurrent ovarian cancer
5. Experimental cancer pharmaceuticals under trial
6. Experimental Drug Fails Against Heart Failure
7. Experimental Drug Fights Prostate Cancer
8. Experimental technique at GUMC offers real-time analysis of breast cancer biopsies
9. Experimental Vaccine Halts Prostate Cancer in Mice
10. Experimental Biology 2008 Todays Research: Tomorrows Health, April 5-9
11. 52 minority scientists receive travel fellowships to Experimental Biology 2008
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Experimental Drug Fights Multiple Sclerosis Activity
(Date:8/4/2015)... ... August 04, 2015 , ... Healthcare ... executives and technology professionals in healthcare and technology markets, today announced significant spikes ... of Defense’s recently-announced Electronic Health Record (EHR) decision. The DOD related numbers solidify ...
(Date:8/3/2015)... ... ... of the economic recovery since the 2008 has been subject to much debate, the fact ... six years. Unemployment has dropped from a 2009 high of 10 percent to 5.9 percent, ... the U.S. stock market is at an all time high, and interest rates at near ...
(Date:8/3/2015)... ... August 04, 2015 , ... The American ... , The new internationally peer-reviewed Guidelines were prepared by members of the AAT ... imaging, in evaluating patients with dental-oral and systemic health-related complaints. , Thermography ...
(Date:8/3/2015)... ... , ... Sutter Health’s California Pacific Medical center announces the appointment of Hamila ... in her role effective immediately and will have responsibility for all aspects of operations ... Health for about 15 years, including the past 7 years as vice president of ...
(Date:8/3/2015)... Mich (PRWEB) , ... August 03, 2015 , ... Since ... country has declined, according to a new publication released today by the AAMC (Association ... black male college graduates over the past three decades, the number of black male ...
Breaking Medicine News(10 mins):Health News:Coverage of DOD’s EHR Decision Reinforces Healthcare IT News’ Leadership 2Health News:Newport Board group, an Advisory Firm Serving the Middle Market, Cautions Businesses on How to Survive the Coming Recession 2Health News:Newport Board group, an Advisory Firm Serving the Middle Market, Cautions Businesses on How to Survive the Coming Recession 3Health News:Newport Board group, an Advisory Firm Serving the Middle Market, Cautions Businesses on How to Survive the Coming Recession 4Health News:American Academy of Thermology (AAT) Publishes First-Ever Guidelines for Oral-Systemic Thermography 2Health News:American Academy of Thermology (AAT) Publishes First-Ever Guidelines for Oral-Systemic Thermography 3Health News:Hamila Kownacki, RN Appointed as New Chief Operating Officer at CPMC 2Health News:New Publication Focuses on the Decline of Black Males in Medicine 2Health News:New Publication Focuses on the Decline of Black Males in Medicine 3Health News:New Publication Focuses on the Decline of Black Males in Medicine 4
... to identify the agricultural areas with the greatest potential for ... ), which is at risk of extinction. The study shows ... Park of the Sierra de Cardea y Montoro, in Crdoba ... this species lives are the most appropriate sites ...
... , , , ... Healthcare, one of the nation,s first and leading providers of kidney ... the recipients of the 2009 Norman S. Coplon Extramural Grant Program. ... and medical centers in the United States and Canada who are ...
... , , , SAN DIEGO, ... company, today announced that the U.S. Court of Appeals for the ... over the validity of its patents that cover the methods for ... thiopurines to reach and maintain desired therapeutic levels (U.S. Patent Nos. ...
... , , Stable Medicare ... Quality Report , , WASHINGTON, Sept. ... Alliance for Quality Nursing Home Care (Alliance) characterized the health care ... as a step in the right direction, and said the process ...
... , WASHINGTON, Sept. 17 More than ... joint Open Letter to Congress declaring that the health care ... act now on meaningful reforms. They state that Congress has a ... , , The Open Letter identifies eight ...
... , , , ... advanced medical and aesthetic devices, introduces Smooth Cool HR/SR, a world-class ... the light based hair removal market. Smooth Cool HR/SR will make ... first thru third. "Smooth Cool HR/SR is designed for the practitioner ...
Cached Medicine News:Health News:Proposal to reintroduce Iberian lynx on abandoned agricultural land 2Health News:Satellite Healthcare Announces the Recipients of the 2009 Norman S. Coplon Extramural Grants 2Health News:Satellite Healthcare Announces the Recipients of the 2009 Norman S. Coplon Extramural Grants 3Health News:Appeals Court Rules in Favor of Prometheus, Upholds the Patentability of Its Claims for Methods of Thiopurine Metabolite Testing 2Health News:Baucus Approach to Financing Health Care Reform Step in Right Direction 2Health News:Leading American Healthcare Experts Press Congress to Act Quickly on Health Reform 2Health News:Leading American Healthcare Experts Press Congress to Act Quickly on Health Reform 3Health News:Leading American Healthcare Experts Press Congress to Act Quickly on Health Reform 4Health News:Eclipse Introduces Smooth Cool HR/SR with Unique Chilling Technology 2
(Date:8/3/2015)... BOULDER, Colo., Aug. 3, 2015  Array BioPharma ... for the fourth quarter and full year of ... Ron Squarer, Chief Executive Officer of Array, noted, ... Phase 3, are on track for regulatory submissions ... in BRAF-mutant melanoma and BRAF-mutant colorectal cancer further ...
(Date:8/3/2015)... Aug. 3, 2015  Charleston Laboratories, Inc., an ... second clinical development program with a Phase 1 ... CL-H1T contains fast-dissolving promethazine and sumatriptan.  ... a treatment for migraine headache pain and migraine-induced ... patients with migraine headaches also suffer from nausea ...
(Date:8/3/2015)... FLORHAM PARK, N.J. , Aug. 3, ... met its primary and secondary endpoints in a phase ... constipation (OIC) in adult patients with chronic non-cancer pain. ... antagonist (PAMORA). This is the third Phase III trial ... endpoints. Study results showed that a 0.2 ...
Breaking Medicine Technology:Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 2Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 3Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 4Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 5Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 6Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 7Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 8Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 9Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 10Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 11Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 12Charleston Laboratories, Inc. Initiates Patient Enrollment in a Phase 1 Study of Charleston's Second Product, CL-H1T 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 4
... SenSage, Inc., a leading provider of ... that it has been selected as Cerner Corporation,s (Nasdaq: ... for its ability to demonstrate significant speed to value ... announced today an expanded alliance with Cerner to offer ...
... Codexis, Inc. (Nasdaq: CDXS ) ... with Teva Pharmaceutical Industries Ltd., the world,s largest ... technology transfer of custom biocatalysts for manufacture of ... have been transferred to pilot manufacturing and a ...
Cached Medicine Technology:SenSage Named Cerner Corporation's 'Accelerate Partner of the Year' 2SenSage Named Cerner Corporation's 'Accelerate Partner of the Year' 3SenSage Named Cerner Corporation's 'Accelerate Partner of the Year' 4Codexis Achieves Development Milestones With Teva 2
CO 2 SMO-Capnograph/Pulse Oximeter...
A software program for simple, efficient pulse oximetry analysis, which enables easy viewing, analysis and report generation for pulse rate and SpO 2 ....
... the next generation in pulse oximetry monitoring ... current family of "digital pulse oximeters, MARSpO ... breakthroughs in signal processing. This provides improved ... superior performance during challenging clinical conditions such ...
The NPB-40 Handheld Pulse Oximeter is both compact and affordable. It is simple to operate, provides spot-check monitoring of SpO 2 and pulse rate, and is compact enough to fit in your pocket....
Medicine Products: